CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Clinical trial NCT04034446 · TERMINATED
Trial details
- NCT number
- NCT04034446
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- TERMINATED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-30
- Primary completion
- 2020-07-21
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.